PARP inhibitors: the story is still unfolding
Tripathy, D.
Oncology 25(11): 1028; 1030
2011
ISSN/ISBN: 0890-9091 PMID: 22106553 Document Number: 649851
Document emailed within 1 workday
Related Documents
Patel, A.; Kaufmann, S.H. 2010: Development of PARP inhibitors: an unfinished story Oncology 24(1): 66; 68Loeb, S.; Schaeffer, E.M. 2009: Optimal therapy in localized prostate cancer: an unfolding story Oncology 23(10): 843; 846
Plummer, R.; Plummer, R. 2015: PARP inhibitors in ovarian and other cancers Clinical Advances in Hematology and Oncology: H&o 13(5): 285-287
Del Rivero, J.; Kohn, E.C. 2017: PARP Inhibitors: the Cornerstone of DNA Repair-Targeted Therapies Oncology 31(4): 265-273
He, Y.-J.; Liu, R.-H.; Ning, C.-Q.; Yu, N.-F. 2013: Research progresses of the PARP inhibitors for the treatment of cancer Yao Xue Xue Bao 48(5): 655-660
Garber, J. 2017: Judy Garber on PARP Inhibitors for Triple-Negative Breast Cancer Oncology 31(11): 814
Griffin, R.J.; Pemberton, L.C.; Rhodes, D.; Bleasdale, C.; Bowman, K.; Calvert, A.H.; Curtin, N.J.; Durkacz, B.W.; Newell, D.R.; Porteous, J.K. 1995: Novel potent inhibitors of the DNA repair enzyme poly(ADP-ribose)polymerase (PARP) Anti-Cancer Drug Design 10(6): 507-514
Palma, J.P.; Rodriguez, L.E.; Bontcheva-Diaz, V.D.; Bouska, J.J.; Bukofzer, G.; Colon-Lopez, M.; Guan, R.; Jarvis, K.; Johnson, E.F.; Klinghofer, V.; Liu, X.; Olson, A.; Saltarelli, M.J.; Shi, Y.; Stavropoulos, J.A.; Zhu, G.-D.; Penning, T.D.; Luo, Y.; Giranda, V.L.; Rosenberg, S.H.; Frost, D.J.; Donawho, C.K. 2008: The PARP inhibitor, ABT-888 potentiates temozolomide: correlation with drug levels and reduction in PARP activity in vivo Anticancer Research 28(5a): 2625-2635
Merritt, D.D.; Liles, B.Z. 1987: Story grammar ability in children with and without language disorder: story generation, story retelling, and story comprehension Journal of Speech and Hearing Research 30(4): 539-552
Merritt, D.D.; Liles, B.Z. 1987: Story grammar ability in children with and without language disorder: story generation, story retelling, and story comprehension Journal of Speech and Hearing Research 30(4): 539-552
Pogrebniak, A.; Schemainda, I.; Pelka-Fleischer, R.; Nüssler, V.; Hasmann, M. 2003: Poly ADP-ribose polymerase (PARP) inhibitors transiently protect leukemia cells from alkylating agent induced cell death by three different effects European Journal of Medical Research 8(10): 438-450
Kumari, S.R.; Mendoza-Alvarez, H.; Alvarez-Gonzalez, R. 1998: Functional interactions of p53 with poly(ADP-ribose) polymerase (PARP) during apoptosis following DNA damage: covalent poly(ADP-ribosyl)ation of p53 by exogenous PARP and noncovalent binding of p53 to the M(r) 85,000 proteolytic fragment Cancer Research 58(22): 5075-5078
Plessow-Wolfson, S.; Epstein, F. 2005: The experience of story reading: deaf children and hearing mothers' interactions at story time American Annals of the Deaf 150(4): 369-378
Chugh, K.S. 1976: Amyloid--an unfolding enigma Journal of the Association of Physicians of India 24(1): 39-41
Lindmark, M.; Vikström, P. 2003: Growth and structural change in Sweden and a story of convergence Finland, 1870–1990: a story of convergence Scandinavian Economic History Review 51(1): 46-74
Gertner, E.; Goodman, R.; Gladman, D.D. 1989: Successive unfolding of two different collagen vascular diseases in the same patient Journal of Rheumatology 16(1): 126-127
Saito, H.; Miki, Y. 2012: PARP (poly(ADP-ribose) polymerase) family Nihon Rinsho. Japanese Journal of Clinical Medicine 70(Suppl 8): 71-77
Rodionova, N.A.; Semisotnov, G.V.; Kutyshenko, V.P.; Uverskiĭ, V.N.; Bolotina, I.A. 1989: Staged equilibrium of carbonic anhydrase unfolding in strong denaturants Molekuliarnaia Biologiia 23(3): 683-692
Aguiar, M.ír.; Van-Dierdonck, J.B.; Stollenwerk, N. 2020: Reproduction ratio and growth rates: Measures for an unfolding pandemic Plos one 15(7): E0236620
Saha, K., B.; Jain, D.C.; Saha, U., C. 2006: Unfolding contraceptive technology: Where Indian population stands today? Journal of Human Ecology 20(2): 125-128